SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 4366.
  • 2
    Ozols RF,Bundy BN,Greer BE, et al. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21: 31943200.
  • 3
    Tay EH,Grant PT,Gebski V,Hacker NF. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol. 2002; 99: 10081013.
  • 4
    Rubin SC,Hoskins WJ,Saigo PE, et al. Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. Gynecol Oncol. 1991; 42: 137141.
  • 5
    Verheijen RH,Massuger LF,Benigno BB, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol. 2006; 24: 571578.
  • 6
    Barakat RR,Sabbatini P,Bhaskaran D, et al. Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol. 2002; 20: 694698.
  • 7
    Tournigand C,Louvet C,Molitor JL, et al. Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission. Gynecol Oncol. 2003; 91: 341345.
  • 8
    Sabbatini P,Spriggs DR. Consolidation for ovarian cancer in remission. J Clin Oncol. 2006; 24: 537539.
  • 9
    Barakat RR,Almadrones L,Venkatraman ES, et al. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol. 1998; 69: 1722.
  • 10
    Armstrong DK,Bundy B,Wenzel L, et al. Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354: 3443.
  • 11
    Markman M,Bundy BN,Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001; 19: 10011007.
  • 12
    Alberts DS,Liu PY,Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996; 335: 19501955.
  • 13
    Naik R,Nordin A,Cross PA,Hemming D,de Barros Lopes A,Monaghan JM. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases. Gynecol Oncol. 2000; 78: 171175.
  • 14
    Bonnefoi H,A'Hern RP,Fisher C, et al. Natural history of stage IV epithelial ovarian cancer. J Clin Oncol. 1999; 17: 767775.
  • 15
    Akahira JI,Yoshikawa H,Shimizu Y, et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol. 2001; 81: 398403.
  • 16
    Bristow RE,Montz FJ,Lagasse LD,Leuchter RS,Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999; 72: 278287.
  • 17
    Curtin JP,Malik R,Venkatraman ES,Barakat RR,Hoskins WJ. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol. 1997; 64: 912.
  • 18
    Munkarah AR,Hallum AV3rd,Morris M, et al. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol. 1997; 64: 1317.
  • 19
    Brunisholz Y,Miller J,Proietto A. Stage IV ovarian cancer: a retrospective study on patient's management and outcome in a single institution. Int J Gynecol Cancer. 2005; 15: 606611.
  • 20
    Alberts DS,Green S,Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 1992; 10: 706717 [erratum J Clin Oncol. 1992;10:1505].
  • 21
    Markman M,George M,Hakes T, et al. Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. J Clin Oncol. 1990; 8: 146150.
  • 22
    Francis P,Rowinsky E,Schneider J,Hakes T,Hoskins W,Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol. 1995; 13: 29612967.
  • 23
    Markman M,Reichman B,Hakes T, et al. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Gynecol Oncol. 1993; 50: 100104.
  • 24
    Husain A,Sabbatini P,Spriggs D, et al. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer. Gynecol Oncol. 1999; 73: 96101.
  • 25
    [No authors listed.] Changes in definitions of clinical staging for carcinoma of the cervix and ovary: International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol. 1987; 156: 263264.
  • 26
    Eitan R,Levine DA,Abu-Rustum N, et al. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma. Cancer. 2005; 103: 13971401.
  • 27
    Winter WE3rd,Maxwell GL,Tian C, et al. Gynecologic Oncology Group study. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007; 25: 36213627.
  • 28
    Los G,Mutsaers PH,van der Vijgh WJ,Baldew GS,de Graaf PW,McVie JG. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 1989; 49: 33803384.
  • 29
    Los G,Verdegaal EM,Mutsaers PH,McVie JG. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991; 28: 159165.
  • 30
    Los G,Mutsaers PH,Lenglet WJ,Baldew GS,McVie JG. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol. 1990; 25: 389394.
  • 31
    Nicholson S,Gooden CS,Hird V, et al. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis. Oncol Rep. 1998; 5: 223226.
  • 32
    Markman M. Rationale for maintenance or consolidation therapy in ovarian cancer. Clin Adv Hematol Oncol. 2003; 1: 176178.
  • 33
    Markman M. Consolidation/maintenance chemotherapy for ovarian cancer. Curr Oncol Rep. 2003; 5: 454458.
  • 34
    Markman M,Liu PY,Wilczynski S, et al. Southwest Oncology Group; Gynecologic Oncology Group. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003; 21: 24602465.
  • 35
    Berek JS,Taylor PT,Gordon A, et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol. 2004; 22: 35073516.
  • 36
    Chi DS,Franklin CC,Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004; 94: 650654.